Top Gainers & Losers on May 18: Gland Pharma, Coforge, PB Fintech, BSE, Voltas, Bharti Airtel Among Top Gainers

Why It Matters

The session shows that earnings‑driven buying in pharma and IT can sustain market momentum even as the rupee weakens and foreign investors pull capital, underscoring the resilience of core growth sectors in India’s equity market.

Key Takeaways

• Gland Pharma rose 15.4% after 96.6% profit surge
• Nifty 50 up 0.03% to 23,649; Sensex to 75,263
• FPIs sold ~₹2.16 lakh crore ($26 bn) equities in 2026 YTD
• IT stocks led gains; Coforge up 5.2%, BSE up 3%

Pulse Analysis

The May 18 session highlighted the delicate balance between macro‑level pressures and sector‑specific strength in India’s equity market. While the rupee slipped to a fresh low of 96.39 per U.S. dollar, and foreign portfolio investors off‑loaded an estimated ₹2.16 lakh crore (about $26 billion) of equities—exceeding the total outflow of 2025—the broader indices managed a modest 0.03% rise. This resilience was anchored by a late‑hour surge in technology and pharmaceutical stocks, which offset declines in financials, autos and metals, and kept the Nifty Midcap and Smallcap indices from deeper falls.

Earnings reports were the primary catalyst for the rally. Gland Pharma’s shares surged 15.4% after the company posted a 96.6% year‑on‑year jump in consolidated profit after tax to ₹366.67 crore (approximately $44 million). The strong performance resonated across the pharma space, providing a boost to the broader market. In parallel, the IT sector delivered robust gains, led by Coforge’s 5.2% rise and solid advances from Persistent Systems, Oracle Financial Services, and Infosys. The collective IT rally underscored the sector’s continued appeal amid global digital transformation trends, while the BSE exchange itself climbed 3%, reflecting confidence in market infrastructure.

For investors, the day’s dynamics suggest that sector‑driven earnings momentum can mitigate currency volatility and foreign outflows, at least in the short term. However, sustained pressure on the rupee and the ongoing geopolitical uncertainty surrounding U.S.–Iran relations remain headwinds. Analysts caution that while value buying in IT and pharma may support the market, a diplomatic breakthrough with Iran could be pivotal for unlocking a decisive upward move. Monitoring foreign investor sentiment and currency trends will be essential for gauging the durability of this modest recovery.